CELYAD SA/ADR (CYAD) Sets New 12-Month Low at $22.17
CELYAD SA/ADR (NASDAQ:CYAD) shares reached a new 52-week low on Thursday . The company traded as low as $22.17 and last traded at $22.17, with a volume of 30684 shares trading hands. The stock had previously closed at $24.31.
A number of research firms have weighed in on CYAD. Zacks Investment Research cut shares of CELYAD SA/ADR from a “hold” rating to a “sell” rating in a research report on Monday, August 27th. ValuEngine upgraded shares of CELYAD SA/ADR from a “sell” rating to a “hold” rating in a research report on Monday, July 2nd. Finally, HC Wainwright began coverage on shares of CELYAD SA/ADR in a research report on Monday, July 2nd. They set a “buy” rating and a $45.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $46.00.
The firm has a market capitalization of $261.52 million, a P/E ratio of -6.82 and a beta of 1.52.
About CELYAD SA/ADR (NASDAQ:CYAD)
Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma.
Featured Article: Put Option
Receive News & Ratings for CELYAD SA/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELYAD SA/ADR and related companies with MarketBeat.com's FREE daily email newsletter.